Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative medications work by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to food. By activating GLP-1 receptors in the pancreas, these agents boost insulin release and inhibit glucagon outpu

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing contrasts in the